cbdMD Inc Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Thomas McGovern - Maxim Group - Analyst : Regain compliance with the continued listing standards by December 5, 2025. Is that a typo? Should it be 2024?

Question: Thomas McGovern - Maxim Group - Analyst : Hey, guys. How's it going? Congrats on the quarter. Yes. So, first question is on sequential sales growth. I'm just curious, last quarter, you guys announced the hiring of some key sales personnel, as well as this revamped strategy that was from my understanding focusing more on the functionality of the products. So maybe you can walk me through first in the second quarter, how much of the sequential improvement can be attributed to this new strategy, these new salespeople? And then maybe if you want to start talking a little bit about the recently published data and how you guys plan if you're planning to incorporate that into your sales approach for marketing?

Question: Thomas McGovern - Maxim Group - Analyst : I understand. I appreciate that color. Next question is actually on the study more specifically. So I was just wondering if you could maybe unpack for us a little bit -- into a little bit more detail on what the actual results of the study was. From my understanding, I read the publication was that the most significant result was in pain reduction or perceived pain between the test group and the control group. Was this the only statistically significant difference in these groups? Or maybe if you could just go into a little bit detail what the researchers concluded from the study that'd be appreciated.

Question: Thomas McGovern - Maxim Group - Analyst : Understood. I appreciate you taking the time to answer my questions.